Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019

Peters, Luisa; Krogmann, Amanda; Hardenberg, Laura von; Bödeker, Katja; Nöhles, Viktor B; Correll, Christoph U.

doi:10.1007/s11920-019-1114-0

Cited by 18 publications

(10 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, patients and providers must plan ahead for any disruption in the dose administration schedule to access oral cabotegravir from the manufacturer and oral rilpivirine from a retail pharmacy. 13 Delayed or missed doses are often unplanned in real-world settings, which may not allow sufficient time to access oral cabotegravir. One practical strategy may be to provide oral bridging with another commercially available antiretroviral combination that is accessible at a local pharmacy, or that the patient may already have on hand at home, such as co-formulated dolutegravir and rilpivirine.…”

Section: Challenges With Long-acting Therapymentioning

confidence: 99%

“…11 Compared to oral agents, LA injectable antipsychotics are associated with lower risk of relapse, fewer hospitalizations, and greater retention on therapy. [11][12][13] In addition, one study found that individuals who were nonadherent to oral antipsychotics were less likely to discontinue LA therapy (p ¼ 0.033) compared with patients on oral therapy. 14 Building upon success in these disease states, LA antiretrovirals are currently being developed for the treatment and prevention of HIV infection.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

Scarsi

Swindells

2021

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

As with other chronic conditions, adherence to daily medications remains a challenge for many individuals living with HIV due to structural, behavioral, and social barriers. Unfortunately, high levels of adherence to antiretroviral therapy are required to maintain virologic suppression. Alternative approaches are being explored to decrease the burden of daily pill administration, including long-acting injectable, oral, and implantable products. Phase 3 data support the efficacy of nanoformulated injectable cabotegravir and rilpivirine for HIV treatment in patients with undetectable viremia, but we have yet to learn how this strategy may benefit those with medication adherence challenges. Despite this, the affected community and HIV providers are very interested in exploring the role of long-acting therapies to address some types of barriers to medication adherence. This review summarizes available information about the potential for long-acting therapy to improve adherence for some patients and outlines associated opportunities and challenges with the implementation of long-acting therapy for the treatment and prevention of HIV.

show abstract

Section: Challenges With Long-acting Therapymentioning

confidence: 99%

mentioning

confidence: 99%

The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

Scarsi

Swindells

2021

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

show abstract

“…J Clin Psychiatry 82:1, January/February 2021 Kim et al improvements in patients with schizophrenia treated with LAI antipsychotics. Specifically, a previous systemic analysis 9 of randomized controlled trials demonstrated the superiority of LAI antipsychotics over oral antipsychotics with respect to functioning and service engagement. Moreover, a prospective study 10 reported that treatment with paliperidone LAI improved functioning, as measured using the Personal and Social Performance scale (PSP), in non-acutely ill, symptomatic patients with schizophrenia.…”

Section: E2mentioning

confidence: 99%

Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration

Kim¹,

Kim²,

Koh³

et al. 2021

J. Clin. Psychiatry

View full text Add to dashboard Cite

“…Several studies have investigated the pros and cons of oral medication versus long acting medication through injections (LAI) [2][3][4][5][6][7][8][9]. Compared to oral antipsychotic treatment, LAI significantly increases the time to symptomatic relapse and re-hospitalisation and reduces mortality [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study

Rise

Stølan

Erdner

et al. 2020

Nordic Journal of Psychiatry

View full text Add to dashboard Cite

Introduction: Three-monthly dosage of paliperidone palmitate entails longer time to relapse after discontinuation, is similarly tolerable and safe compared to monthly injections of paliperidone palmitate and is beneficial for the caregivers. However, few studies have so far explored in depth the patients' experiences with paliperidone palmitate medication every three months, or with switching from monthly to three-monthly injections of paliperidone palmitate. Material and methods: A qualitative study based on individual interviews with persons with schizophrenia who receive three-monthly paliperidone palmitate in Norway, Sweden and Denmark. Data was analysed according to qualitative content analysis. Results: Twenty-four patients, 16 men and 8 women, took part in individual interviews. The patients' mental health care professionals mainly recommended the switch to three-monthly paliperidone palmitate, and few or no disadvantages were described. According to the patients, three-monthly paliperidone palmitate had several advantages, such as less frequent injections, less administration and planning and less focus on the illness. In addition, the participants described feeling more stability, being more physically and socially active, and that improvement processes were supported. For some, the use involved practical and economic challenges, and some worried whether the medicine 'wore off' before the next injection. According to the patients, switching to three-monthly paliperidone palmitate did not influence the frequency or content of patients' interaction with health care professionals. Conclusion: Switching from monthly to three-monthly injections with paliperidone palmitate seems to be experienced as advantageous for patients with schizophrenia.

show abstract

Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019

Cited by 18 publications

References 82 publications

The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration

Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study

Contact Info

Product

Resources

About